Additional Customer Wins for New Provantis Release

18 April 2013

Instem plc
("Instem", the "Company" or the "Group")

Additional Customer Wins for New Provantis Release

Strong customer uptake of major new upgrade of Provantis

Instem (AIM:INS), a leading provider of IT solutions to the global early development healthcare market, is pleased to announce its latest new customer signing and additional client upgrades for Provantis 9, the next generation of Provantis, Instem’s study management software suite.

The latest new customer signing is a leading Chinese government research laboratory, while existing clients upgrading to the new release in recent months include the M.D. Anderson Cancer Center, Roche, the NIEHS, a global top 10 pharma company, a mid-tier French pharma company and a leading American multi-national chemical corporation. These sign-ups and upgrades bring to 17 the total number of sites implementing Provantis 9, building on a good level of signings in 2012, which included the US National Institute of Allergy and Infectious Diseases, the Beijing National Centre for the Safety Evaluation of Drugs, Lovelace Respiratory Research, Seventh Wave and JOINN Laboratories. Three quarters of these Provantis 9 sites are in the US and China with the balance in Europe.

Provantis 9 represents a major new release of Instem’s core product suite. It was delivered in July 2012 after Instem completed a significant, phased multi-year product redevelopment, designed to further enhance efficiencies and reduce study timelines while supporting the changes in laboratory working practices brought about by the structural changes in the pharma market. It takes advantage of the latest capabilities of the underlying Microsoft┬« and Oracle┬« platform technologies. Customer feedback indicates that unique Provantis capabilities that improve operational efficiency and reduce study timelines are proving to be compelling differentiators in their selection of study management software.

Phil Reason, CEO of Instem plc, commented, “Instem is delighted with the very positive response so far to Provantis 9 from both existing and new customers, particularly those in Europe where the pharma market is recovering more slowly. We are committed to remaining at the forefront of the early development study management industry, providing our clients with the tools to bring new products safely and efficiently to market. We are seeing strong uptake not only from current customers looking to achieve additional levels of automation and efficiency, but also from new customers in key emerging markets such as China. Instem is now firmly established as the leading provider in China, which is on track to become the second largest pharmaceutical market in the world after the US.”

For further information, please contact:

Instem plc www.instem.com
Phil Reason, CEO +44 (0) 1785 825600
Nigel Goldsmith, CFO  
N+1 Singer (Nominated Adviser & Broker) +44 (0) 20 7496 3000
Richard Lindley  
Nick Owen  
James White  
Wallbrook Financial PR Tel: +44 (0) 20 7933 8000
Paul Cornelius or instem@walbrookpr.com
Sam Allen  
Helen Cresswell  
Paul Whittington  

About Instem

Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidlyexpanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.

Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 450 clients through full service offices in the United States, United Kingdom and China with additional locations in Japan and India.

To learn more about Instem solutions and its mission, please visit instem.com.